



**Dr. Ina Zschocke**  
Executive Director  
Therapeutic Areas



**Dr. Peter Weisenseel**  
Senior Medical Director  
Inhouse Clinic

**SCIderm GmbH**  
(a company of TFS Group)

Drehbahn 1-3  
20354 Hamburg, Germany

Tel. +49 40 55 44 01 0  
Fax +49 40 55 44 01 291

[www.tfscro.com](http://www.tfscro.com)

BVMA member since 2011  
Audits passed in 2011, 2014  
and 2017



It's all about trust

**SCIderm**  
unsurpassed in dermatological research  
Scientific Research · Clinical Studies · Innovative Consulting

## HISTORY AND MISSION

TFS International is the leading global mid-size clinical CRO focused on small and mid-size life science customers. TFS employs +850 professionals throughout 21 countries and delivers clinical research services in +40 countries. Our partnering approach with customers is based on our four business principles – commitment, flexibility, value creation and global reach. Our core therapeutic specialties are Dermatology, Oncology, Ophthalmology, Immunology, CNS, Cardiology and Endocrinology.



## HIGHLIGHTS

**Services:** TFS partners its customers in the life science sector in 3 main areas:

- ▷ Global Clinical Development, represented by TFS Develop
- ▷ Flexible resourcing, represented by TFS People and
- ▷ Real World Evidence, represented by TFS Evidence (to be launched in 2017)

Therapeutic Specialization: Through the acquisition of the German dermatology specialist SCIderm, TFS is a global leader in dermatology with the ability to reach 1200 investigational sites in Europe and North America.

## SERVICES

### 1. Contract Research Organization:

- ▷ Study planning & preparation
- ▷ Notification & submission
- ▷ Drug Safety
- ▷ Data management and statistics

### 2. Clinical Consulting:

- ▷ Patient oriented study goals
- ▷ Top KOL indication insights
- ▷ Customized study design
- ▷ Local regulatory advice
- ▷ Educational programs

### 3. Lab Research

- ▷ Diagnostic procedures
- ▷ Molecular biologic tests
- ▷ Quantitative RNA analysis

### 4. Study Site & Management of Site Network

- ▷ High recruitment in-house investigator site
- ▷ Access to 1200 sites & 180,000 patients in Europe & North America
- ▷ Maximized trial performance